- Home
- RCUS vs SABR Comparison
RCUS vs SABR Comparison
Compare RCUS & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- SABR
- Stock Information
- Founded
- RCUS 2015
- SABR 2006
- Country
- RCUS United States
- SABR United States
- Employees
- RCUS N/A
- SABR 6253
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- SABR Computer Software: Programming Data Processing
- Sector
- RCUS Health Care
- SABR Technology
- Exchange
- RCUS Nasdaq
- SABR Nasdaq
- Market Cap
- RCUS 906.4M
- SABR 1.2B
- IPO Year
- RCUS 2018
- SABR 2014
- Fundamental
- Price
- RCUS $9.60
- SABR $3.26
- Analyst Decision
- RCUS Buy
- SABR Hold
- Analyst Count
- RCUS 8
- SABR 5
- Target Price
- RCUS $20.86
- SABR $4.12
- AVG Volume (30 Days)
- RCUS 891.1K
- SABR 4.8M
- Earning Date
- RCUS 08-07-2025
- SABR 07-31-2025
- Dividend Yield
- RCUS N/A
- SABR N/A
- EPS Growth
- RCUS N/A
- SABR N/A
- EPS
- RCUS N/A
- SABR N/A
- Revenue
- RCUS $141,000,000.00
- SABR $3,023,296,000.00
- Revenue This Year
- RCUS N/A
- SABR $2.99
- Revenue Next Year
- RCUS $28.73
- SABR $3.59
- P/E Ratio
- RCUS N/A
- SABR N/A
- Revenue Growth
- RCUS N/A
- SABR 2.56
- 52 Week Low
- RCUS $6.50
- SABR $1.93
- 52 Week High
- RCUS $18.98
- SABR $4.63
- Technical
- Relative Strength Index (RSI)
- RCUS 53.46
- SABR 59.15
- Support Level
- RCUS $9.14
- SABR $2.95
- Resistance Level
- RCUS $9.62
- SABR $3.21
- Average True Range (ATR)
- RCUS 0.44
- SABR 0.14
- MACD
- RCUS 0.04
- SABR -0.02
- Stochastic Oscillator
- RCUS 62.85
- SABR 50.00
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company announced a planned sale of its growing hotel IT solutions division (9% of revenue) to TPG for $960 million in net proceeds, which is scheduled to close in late 2025. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.